Compass Pathways completes FDA NDA for COMP360 psilocybin in treatment-resistant depression
FROM THE WIRE · FINANCE.YAHOO.COM
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe completed NDA is a key regulatory step that can move the stock ahead of a possible 2027 launch.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Compass Pathways completed its NDA submission to the FDA for COMP360 psilocybin in treatment-resistant depression.
- 02The filing is supported by two Phase 3 trials and a Phase 2b study that each met their primary endpoint.
- 03Launch is expected in H1 2027, subject to FDA approval.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets